Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flow from operating activities:
Net loss	$ (57,892)	$ (196,295)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation and amortization	7,922	9,324
Non cash lease expense	160	(13)
Provision for credit losses	457	1,233
Provision for inventory obsolescence	(186)	1,328
Change in fair value of warrant liabilities	(398)	(6,164)
Inventory impairment	466	5,384
Goodwill impairment		112,347
IPR&D impairment		107,800
Stock-based compensation expense	11,569	15,017
Change in fair value of contingent consideration	(193)	(104,339)
Acquired in-process research and development		3,000
Issuance of common stock for stem-cells to be used in research and development		1,000
Issuance of common stock to Palantir as consideration for settlement agreement	175
Issuance of common stock to Yorkville for debt extension and SEPA commitment fee	317	712
Issuance of common stock as compensation expense	158
Discounts arising from RWI loan arrangement - related party		2,151
Fair value of warrant modification for professional services		403
Loss on debt extinguishment	3,908
Change in fair value of debt	492	1,177
Change in fair value of contingent stock consideration		(159)
Non cash interest expense	4,144
Other, net	300	4,157
Changes in operating assets and liabilities:
Accounts receivable	(3,968)	(6,827)
Inventory	6,284	(865)
Prepaid expenses and other assets	905	5,606
Accounts payable	9,239	8,497
Accrued expenses and other liabilities	12,634	(1,128)
Accrued R&D software	(3,500)	(3,834)
Lease liabilities - operating	371	275
Deferred revenue	235	1,528
Net cash used in operating activities	(6,401)	(38,685)
Cash flow from investing activities:
Capital expenditures	(161)	(1,048)
Rebound asset acquisition	(1,500)
Purchase of acquired in-process research and development		(3,000)
Proceeds from Sanuwave convertible note	2,175
Net cash provided by (used in) investing activities	514	(4,048)
Cash flow from financing activities:
Proceeds from warrants and short-term debt - related parties	15,000	18,369
Repayments of short-term debt - unaffiliated	(17,374)	(16,811)
Proceeds from the sale of common stock in ATM offering		136
Proceeds from issuance of short-term debt - unaffiliated	3,622	2,000
Payment of SEPA commitment fee	(25)
Repayments of short-term debt - related parties	(146)
Proceeds from PIPE financing	6,000	12,750
Proceeds from the exercise of stock options	58	304
Tax withholding on vesting of restricted stock units	(434)	(101)
Proceeds from registered direct offering		9,000
Payments of PIPE and other issuance costs		(1,553)
Net cash provided by financing activities	6,701	24,094
Net increase (decrease) in cash, cash equivalents and restricted cash	814	(18,639)
Cash, cash equivalents and restricted cash at beginning of year	10,163	28,802
Cash, cash equivalents and restricted cash at end of year	10,977	10,163
Supplemental disclosure of cash flow information:
Cash paid for interest	144	1,073
Supplemental non-cash investing and financing activities:
Property and equipment included in accounts payable and accrued expenses	(87)	(223)
Common stock issued for short-term debt conversion	1,700	4,599
Modification of C.V. Starr warrants in connection with forbearance	51
Issuance of RWI warrants in connection with forbearance	1,162
Issuance of warrants on senior secured bridge loan		2,002
Reduction of right-of-use assets and associated lease liabilities - operating due to lease modification		(2,083)
PIPE related costs included in accrued expenses		(69)
Interest accrued on senior secured loans within long-term debt - related parties		(1,770)
Contingent consideration accrued in connection with Rebound asset acquisition	650
Inventory acquired in connection with Rebound asset acquisition	2,150
Reclassification of warrants from liability classified to equity classified	2,970
Assumption of short-term debt - unaffiliated by related party	$ 2,333